Arca
Skip to content
Tools
Tools

Tinnitus

Drug research and approvals for tinnitus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 42 studies of tinnitus are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.

  • Recruiting worldwide: 42
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest start dates first, of 42 recruiting on ClinicalTrials.gov ↗

Drug pipeline

3 in phase 3, 12 in phase 2, 4 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Esketamine
Phase 3 Glutamate [NMDA] receptor negative allosteric modulator
Neramexane
Phase 3 Neuronal acetylcholine receptor; alpha9/alpha10 antagonist
Oxytocin
Phase 3 Oxytocin receptor agonist
Gabapentin
Phase 2 Voltage-gated calcium channel modulator
Etanercept
Phase 2 TNF-alpha inhibitor
Paroxetine
Phase 2 Serotonin transporter inhibitor
Botulinum toxin type a
Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
Brexanolone
Phase 2 GABA-A receptor; anion channel positive allosteric modulator
Vardenafil
Phase 2 Phosphodiesterase 5A inhibitor
Ketamine
Phase 2 Glutamate [NMDA] receptor negative allosteric modulator
Vestipitant
Phase 2 Neurokinin 1 receptor antagonist
Selurampanel
Phase 2 Glutamate receptor ionotropic AMPA antagonist
Sulodexide
Phase 2
Zinc ion
Phase 2
Modafinil
Phase 1 Dopamine transporter inhibitor
Acamprosate
Phase 1 Glutamate [NMDA] receptor antagonist
Cannabinol
Phase 1
Lidocaine
Early phase 1 Sodium channel alpha subunit blocker

How its trials ended

344 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 67 whose ending is known, 37% met their primary endpoint, 13% missed it and 49% stopped early.

  • Completed, result not reported15946%
  • Ongoing6619%
  • Status unknown5215%
  • Met its primary endpoint257%
  • Stopped: other or unclear247%
  • Missed its primary endpoint93%
  • Stopped: lack of efficacy31%
  • Stopped: enrollment or feasibility21%
  • Stopped: sponsor or business decision21%
  • Stopped: funding21%

Trials authorized in Canada

Newest first; search them all in Canada trials
Feb 27, 2014Am-101 in the post-acute treatment of peripheral tinnitus 1 (AMPACT1) - an open-label extension to the TACTT2 studyEsketamine (AM-101)Auris Medical IncClosed
Dec 23, 2013Efficacy and safety of AM-101 in the treatment of acute peripheral tinnitus 2 (TACTT2)EsketamineAuris Medical IncClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.